San Juan

Futó vizsgálatok

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· 3. fázis· Forrás

• Toboroz

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· 3. fázis· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· 3. fázis· Forrás

• Toboroz

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· 3. fázis· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· Forrás

• Toboroz

  Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

  NCT05952024· 2. fázis· Forrás

• Toboroz

  Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT06350097· 3. fázis· Forrás

• Toboroz

  Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  NCT06357533· 3. fázis· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· Forrás

• Fut, nem toboroz

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· 3. fázis· Forrás

• Fut, nem toboroz

  Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

  NCT05301842· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák3 toboroz
• 2-es típusú cukorbetegség1 toboroz
• Áttétes emlőrák1 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)1 toboroz
• Follikuláris limfóma1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Máj- és epeúti rák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· Forrás

• Toboroz

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· 3. fázis· Forrás

• Leállították

  A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

  NCT05864391· 1. fázis· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· 3. fázis· Forrás